73873-87-7

Basic information

• Product Name: Iloprost
• Synonyms: CILOPROST;ILOPROST;6,9ALPHA-METHYLENE-11ALPHA,15S-DIHYDROXY-16-METHYL-PROSTA-5E,13E-DIEN-18-YN-1-OIC ACID;Iloprost (for research only)
• CAS NO: 73873-87-7
• Molecular Formula: C22H32O4
• Molecular Weight: 360.49
• Product Categories: Prostaglandins
• Mol File: 73873-87-7.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 539.2oC at 760 mmHg
• Flash Point: 294oC
• Appearance: /
• Density: 1.21g/cm3
• Vapor Pressure: 7.06E-14mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: Amber Vial, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• Stability: Light Sensitive
• CAS DataBase Reference: Iloprost(CAS DataBase Reference)
• NIST Chemistry Reference: Iloprost(73873-87-7)
• EPA Substance Registry System: Iloprost(73873-87-7)

Safety Data

• Hazardous Substances Data: 73873-87-7(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 73873-87-7 differently. You can refer to the following data:
1. Treatment of pulmonary hypertension (prostacyclin analogue).
2. A synthetic analogue of Prostacyclin (PGI2) used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud''s phenomenon and ischemia. It acts through elevation of cAMP by binding to the prostacyclin receptor (IP receptor). Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets with an ED50 of about 13 nM. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time.

General Description

This more chemically and biologically stable derivativeof prostacyclin is available as a solution (10 μg/mL)for nasal inhalation (Ventavis by Actelion) via a preciselycalibrated inhalation device for the treatment of pulmonaryarterial hypertension (PAH). Patients inhale 6 to 8 puffs ofaerosolized iloprost every 2 to 3 hours to produce a directvasodilatory effect on pulmonary blood vessels, therebydecreasing vascular resistance. Side effects of coughing,flushing, headaches, and jaw pain have been most commonlyreported.

Clinical Use

Iloprost is administered as an inhalation solution of a prostacyclin analog for the treatment of NYHA class III and class IV PAH. The drug also can be administered as an IV infusion. It is stable at room temperature and to light, with a body half-life of 30 minutes. Iloprost has approximately 10 times greater potency than prostacyclin as a vasodilator of the pulmonary blood vessels; this greater potency of inhaled iloprost results from coating of the drug on the alveoli of the lungs.

Side effects

Studies have reported minor side effects, such as coughing, headaches, and jaw pain.

Drug interactions

Potentially hazardous interactions with other drugs Anticoagulants: enhanced anticoagulant effect and increased risk of bleeding with heparin, coumarins and phenindione, as iloprost inhibits platelet aggregation. Increased risk of bleeding with NSAIDs, aspirin, clopidogrel, eptifibatide and tirofiban.

Metabolism

On intravenous infusion iloprost is rapidly cleared from the plasma by oxidation. About 80% of the metabolites are excreted in urine and 20% in the bile.

InChI:InChI=1/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18?,19-,20+,21+/m0/s1